



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 163865

TO: Ralph J Gitomer
Location: 3d65 / 3c18
Art Unit: 1655
Wednesday, September 14, 2005

Case Serial Number: 10/650482

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

FIGURE 2A and 2B: Full length human GADD34-Like (GADD34L) cDNA sequence (SEQ ID NO: 1). The open reading frame encoding the full length human GADD34L protein is encompassed by nucleotides 407 through 2548, inclusive. The start codon for the GADD34L protein is bold and underlined (**ATG**, **FIGURE 2A**), while the stop codon is underlined (**TGA**, **FIGURE 2B**). This sequence is identical to that of Genbank Accession Numbers NM_032833 and AK027650.

FIGURE 3: Full length human GADD34-Like (GADD34L) amino acid sequence (SEQ ID NO: 2). This protein sequence is encoded by nucleotides 407 through 2545, inclusive, of the full length human GADD34L cDNA sequence (see Figure 2A and 2B). This sequence is identical to that of Genbank Accession Number NM_032833.

FIGURE 4A, 4B, 4C, and 4D: Full length mouse GADD34-Like (GADD34L) cDNA sequence (SEQ ID NO: 3). The open reading frame encoding the full length mouse GADD34L protein is encompassed by nucleotides 462 through 2558, inclusive. The start codon for the GADD34L protein is bold and underlined (**ATG**, **FIGURE 4A**), while the stop codon is underlined (**TGA**, **FIGURE 4B**).

FIGURE 5: Full length mouse GADD34-Like (GADD34L) amino acid sequence (SEQ ID NO: 4). This protein sequence is encoded by nucleotides 462 through 2555, inclusive, of the full length mouse GADD34L cDNA sequence (see Figure 4A, 4B, 4C and 4D).

FIGURE 6: Inhibition of endogenous GADD34L protects cells against oxidative toxicity. The bar graphs show percent survival of HT22 cells following exposure to toxic amounts of glutamate. HT22 cells were treated with 70 μ M 22P19 for 24 or 48h (top panel), or left untransfected (NTx), mock transfected, transfected with GADD34L siRNA, or transfected with control or CD2 siRNA (bottom panel), and then exposed to the indicated concentrations of glutamate for 18 hours. 100% survival is defined as the level of MTT ((3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, Sigma) cleavage in cells that had not been exposed to glutamate in each treatment group. Shown are the means \pm SEM of a representative experiment performed in duplicate and repeated

four times. There was dramatically improved cell survival following pre-treatment with 22P19, or RNAi-based inhibition of GADD34L. 22P19 is a chemical inhibitor of GADD34L isolated in a high-throughput screen based on its ability to protect cells from tunicamycin toxicity.

5

FIGURE 7: The structure of 22P19. The chemical compound called 22P19 was isolated by screening the Chembridge™ library (Chembridge San Diego, CA) for compounds that protect PC-12 cells from death induced by prolonged exposure to tunicamycin.

10

DETAILED DESCRIPTION OF THE INVENTION

Definitions:

The terms used in this specification generally have their ordinary meanings in the art, within the context of the invention, and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the devices and methods of the invention and how to make and use them. For convenience, certain terms are highlighted, for example using italics and/or quotation marks. The use of highlighting has no influence on the scope and meaning of a term; the scope and meaning of a term is the same, in the same context, whether or not it is highlighted. It will be appreciated that the same thing can be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein, nor is any special significance to be placed upon whether or not a term is elaborated or discussed herein. Synonyms for certain terms are provided. A recital of one or more synonyms does not exclude the use of other synonyms. The use of examples anywhere in this specification, including examples of any terms discussed herein, is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to the preferred embodiments.

30

Primary reactive oxygen species (ROS) include, but are not limited to, superoxide radical, hydrogen peroxide, hydroxyl radical, and ortho-quinone derivatives of

SEQUENCE LISTING

<110> Ron, David
Jousse, Celine

<120> METHODS OF SCREENING TEST COMPOUNDS USING GADD34L, AN eIF2alpha-SPECIFIC PHOSPHATASE SUBUNIT

<130> 5986/1L712-US1

<150> US 60/408,679

<151> 2002-09-06

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 2942

<212> DNA

<213> Homo sapiens

```

<400> 1
atattgggct tcgcttcac cgcaccagcc ggcctaccca gtccttcggt tatcgcggtg      60
ctcaggggct tttcaaccct ctgtcagtcg gaaaaccatc gccgaggccg tggggggact      120
cctatccatg gtgttgaagc gtcgagccga ctagggaacc tccttccccg ccaggatgga      180
agtcgcatca gtcgcgcct attgcgcggg ctgttcttcc ctgtgttctg ccgcccgtg      240
ccgcattcgc tgccctctgt ggcttttctg ctggctcgaa gatcggcctg gagcagcgac      300
gccaccgctg ggcaaggccg agactctgta ggcttcctcc gaatcccgtc gacctccagc      360
cgctgagcgc cgcggcccta cctgagagac tgtcaagaaa aaggagatgg agccggggac      420
aggcggatcg cggaaacggc ttggccctcg ggcgggcttc cggttctggc cacccttttt      480
ccctcggcga tcgcaagcag gctcttctaa gttcccgacg cctcttggcc cggaaaactc      540
cgggaacccc aactgctttt cctctgcccc gcccgagact cgggtcagtt actggacgaa      600
actgctctcc cagctccttg cgcgcctccc cggattgctt cagaagggtc taatttgag      660
ccaacttttc ggtggaatgt ttccgaccag atggctagat tttgctggag tctacagcgc      720
cctgagagcc ctgaagggac gggagaaacc agccgcccc acagcgaga aatctttgag      780
ttcgctgcag ctgcactcct cagacccttc ggtcaccagt ccccttgatt ggctagagga      840
ggggatccac tggcaatact cgcggccaga cctaaaattg gagcttaagg ccaaggggag      900
tgctttggac cctgcagcac aggtttttct cttagagcag cagctgtggg gagtggagct      960
gttgcccagt agccttcaat ccgctctgta ctctaaccgg gaacttggct cttcgccctc     1020

```

tgggcctcta aacattcaac gcatagacaa tttcagtgtg gtatcctatt tgctgaaccc	1080
ttcctacctg gactgctttc ctaggctaga agtcagctat cagaacagtg atggaaatag	1140
cgaggtagtc ggcttccaga cactaacccc agagagcagc tgcctgagag aggaccattg	1200
tcatccccag ccgctgagtg cagaactcat tccggcctcg tggcagggat gtccacctct	1260
ttctacggaa ggctaccag aaattcacca tcttcgcatg aaacggctgg aattccttca	1320
acaggctaac aaggggcaag atttaccac ccctgaccag gataatggct accacagcct	1380
ggaggaggaa cacagccttc tccggatgga tccaaaacac tgcagagata acccaacaca	1440
gtttgttctt gctgctggag acattcctgg aaacaccag gaatccactg aagaaaaaat	1500
agaattatta actacagagg ttccacttgc tttggaagaa gagagccctt ctgagggtg	1560
tccatctagt gagataccta tggaaaagga gcctggagag ggccgaataa gtgtagttga	1620
ttactcatac ctagaagggtg accttcccat ttctgccaga ccagcttgta gtaacaaact	1680
gatagattat attttgggag gtgcattccag tgacctggaa acaagttctg atccagaagg	1740
tgaggattgg gatgagggaag ctgaggatga tggttttgat agtgatagct cactgtcaga	1800
ctcagacctt gaacaagacc ctgaagggtt tcacctttgg aactctttct gcagtgtaga	1860
tccttataat cccagaact ttacagcaac aattcagact gctgccagaa ttgttctga	1920
agagccttct gattcagaga aggatttgtc tggcaagtct gatctagaga attcctcca	1980
gtctggaagc cttcctgaga cccctgagca tagttctggg gaggaagatg actgggaatc	2040
tagtgcagat gaagcagaga gtctcaaact gtggaactca ttctgtaatt ctgatgaccc	2100
ctacaaccct ttaaatttta aggtcctttt tcaaacatca ggggaaaatg agaaaggctg	2160
tcgtgactca aagaccccat ctgagtccat tgtggccatt tctgagtgtc acaccttact	2220
ttcttgtaag gtgcagctgt tggggagcca agaaagtga tgtccagact cggtagagcg	2280
tgacgttctt tctggaggaa gacacacaca tgtcaaaaga aaaaaggtaa ccttccttga	2340
agaagttact gagtattata taagtgggtg tgaggatcgc aaaggacat gggagaat	2400
tgcaagggat ggatgcaggt tccagaaacg aattcaagaa acagaagatg ctattggata	2460
ttgcttgaca tttgaacaca gagaaagaat gttaataga ctccaggga catgcttcaa	2520
aggacttaat gttctcaagc aatgttgagt tggcagcctg tagtcctagc tagcatacac	2580
tacctcttac ctgagagggtg tcttttaaaa acaaatcttg gcagctgtcc tttgacattt	2640
tttttttag aggaatgta acttgatct agtttaattt tttttttgc aacatatccc	2700
actcagaaac attcaggttt gaagccagcc ctgataatga aggatgaact agtgtgattt	2760

ctaatacctcc cttttttgat ttagttggat gtgcttttaa atgtcctttg cctgcatgag 2820
 gtggaaaggg gacctttttg agttgtcatt ttgcactttc aaaacttatt ttcttggaaa 2880
 acaatattta tagggcttaa agcccathtt catttctaata ctaaattatg tgtgcctatc 2940
 tg 2942

<210> 2
 <211> 713
 <212> PRT
 <213> Homo sapiens

<400> 2

Met Glu Pro Gly Thr Gly Gly Ser Arg Lys Arg Leu Gly Pro Arg Ala
 1 5 10 15

Gly Phe Arg Phe Trp Pro Pro Phe Phe Pro Arg Arg Ser Gln Ala Gly
 20 25 30

Ser Ser Lys Phe Pro Thr Pro Leu Gly Pro Glu Asn Ser Gly Asn Pro
 35 40 45

Thr Leu Leu Ser Ser Ala Gln Pro Glu Thr Arg Val Ser Tyr Trp Thr
 50 55 60

Lys Leu Leu Ser Gln Leu Leu Ala Pro Leu Pro Gly Leu Leu Gln Lys
 65 70 75 80

Val Leu Ile Trp Ser Gln Leu Phe Gly Gly Met Phe Pro Thr Arg Trp
 85 90 95

Leu Asp Phe Ala Gly Val Tyr Ser Ala Leu Arg Ala Leu Lys Gly Arg
 100 105 110

Glu Lys Pro Ala Ala Pro Thr Ala Gln Lys Ser Leu Ser Ser Leu Gln
 115 120 125

Leu Asp Ser Ser Asp Pro Ser Val Thr Ser Pro Leu Asp Trp Leu Glu
 130 135 140

Glu Gly Ile His Trp Gln Tyr Ser Pro Pro Asp Leu Lys Leu Glu Leu
 145 150 155 160

Lys Ala Lys Gly Ser Ala Leu Asp Pro Ala Ala Gln Ala Phe Leu Leu
165 170 175

Glu Gln Gln Leu Trp Gly Val Glu Leu Leu Pro Ser Ser Leu Gln Ser
180 185 190

Arg Leu Tyr Ser Asn Arg Glu Leu Gly Ser Ser Pro Ser Gly Pro Leu
195 200 205

Asn Ile Gln Arg Ile Asp Asn Phe Ser Val Val Ser Tyr Leu Leu Asn
210 215 220

Pro Ser Tyr Leu Asp Cys Phe Pro Arg Leu Glu Val Ser Tyr Gln Asn
225 230 235 240

Ser Asp Gly Asn Ser Glu Val Val Gly Phe Gln Thr Leu Thr Pro Glu
245 250 255

Ser Ser Cys Leu Arg Glu Asp His Cys His Pro Gln Pro Leu Ser Ala
260 265 270

Glu Leu Ile Pro Ala Ser Trp Gln Gly Cys Pro Pro Leu Ser Thr Glu
275 280 285

Gly Leu Pro Glu Ile His His Leu Arg Met Lys Arg Leu Glu Phe Leu
290 295 300

Gln Gln Ala Asn Lys Gly Gln Asp Leu Pro Thr Pro Asp Gln Asp Asn
305 310 315 320

Gly Tyr His Ser Leu Glu Glu Glu His Ser Leu Leu Arg Met Asp Pro
325 330 335

Lys His Cys Arg Asp Asn Pro Thr Gln Phe Val Pro Ala Ala Gly Asp
340 345 350

Ile Pro Gly Asn Thr Gln Glu Ser Thr Glu Glu Lys Ile Glu Leu Leu
355 360 365

Thr Thr Glu Val Pro Leu Ala Leu Glu Glu Glu Ser Pro Ser Glu Gly
370 375 380

Cys Pro Ser Ser Glu Ile Pro Met Glu Lys Glu Pro Gly Glu Gly Arg

385	390	395	400
Ile Ser Val Val Asp Tyr Ser Tyr Leu Glu Gly Asp Leu Pro Ile Ser	405	410	415
Ala Arg Pro Ala Cys Ser Asn Lys Leu Ile Asp Tyr Ile Leu Gly Gly	420	425	430
Ala Ser Ser Asp Leu Glu Thr Ser Ser Asp Pro Glu Gly Glu Asp Trp	435	440	445
Asp Glu Glu Ala Glu Asp Asp Gly Phe Asp Ser Asp Ser Ser Leu Ser	450	455	460
Asp Ser Asp Leu Glu Gln Asp Pro Glu Gly Leu His Leu Trp Asn Ser	465	470	475
Phe Cys Ser Val Asp Pro Tyr Asn Pro Gln Asn Phe Thr Ala Thr Ile	485	490	495
Gln Thr Ala Ala Arg Ile Val Pro Glu Glu Pro Ser Asp Ser Glu Lys	500	505	510
Asp Leu Ser Gly Lys Ser Asp Leu Glu Asn Ser Ser Gln Ser Gly Ser	515	520	525
Leu Pro Glu Thr Pro Glu His Ser Ser Gly Glu Glu Asp Asp Trp Glu	530	535	540
Ser Ser Ala Asp Glu Ala Glu Ser Leu Lys Leu Trp Asn Ser Phe Cys	545	550	555
Asn Ser Asp Asp Pro Tyr Asn Pro Leu Asn Phe Lys Ala Pro Phe Gln	565	570	575
Thr Ser Gly Glu Asn Glu Lys Gly Cys Arg Asp Ser Lys Thr Pro Ser	580	585	590
Glu Ser Ile Val Ala Ile Ser Glu Cys His Thr Leu Leu Ser Cys Lys	595	600	605
Val Gln Leu Leu Gly Ser Gln Glu Ser Glu Cys Pro Asp Ser Val Gln	610	615	620

Arg Asp Val Leu Ser Gly Gly Arg His Thr His Val Lys Arg Lys Lys
625 630 635 640

Val Thr Phe Leu Glu Glu Val Thr Glu Tyr Tyr Ile Ser Gly Asp Glu
645 650 655

Asp Arg Lys Gly Pro Trp Glu Glu Phe Ala Arg Asp Gly Cys Arg Phe
660 665 670

Gln Lys Arg Ile Gln Glu Thr Glu Asp Ala Ile Gly Tyr Cys Leu Thr
675 680 685

Phe Glu His Arg Glu Arg Met Phe Asn Arg Leu Gln Gly Thr Cys Phe
690 695 700

Lys Gly Leu Asn Val Leu Lys Gln Cys
705 710

<210> 3
<211> 5468
<212> DNA
<213> Mus musculus

<400> 3
cggctcctccg tctcgccctg cagcttccgg gtgtgcggct gcggccattt tgagcttcgc 60
ttctttgctc cctcgccctg caccagcca ccctttccgc cttggcggtt cgcgcctccg 120
tgcgggccac cggaaacgcc gccgtcgtct ccgtcgccgc cgcgcgaggg agggctctct 180
ctatggtgga gcatctcac acggcctagg acgtctcctt ccctagccgg gatggacctt 240
accgcggctg ccaccgcttg cgcgggcctc tgggcgctcc ggtgcagcac tcgttgcgga 300
agccgccgct ctctgggctt cctctgccgg cgcgggaatc ggactgcagt accactccg 360
tggtgaggca aggcggagac tgttagacc tcggatccag cctgcgctga cgccgctgag 420
ctctgtcctc ctctgtctg agaagccgcc aaggaaagga gatggagaca ggaacgcaca 480
gggcccggaa ggggcctggc cctcggttgg gtccttgggt ccggctgccc ttccttcggc 540
gatgcacgc ctgctcttcg gattcccg cgccttctc tcgacaaaat cccgggaact 600
ccgtctgcc cgagcgtcg accaggtact ggaccaaatt gctttctcag ctcttgccc 660
tgctccctag cctattccag aagctgctgc ttggagcca gctttccggg ggctgattc 720
ctaccagatg gctagatttt gccgcaagtt acagcgccct gagagcttcg agaggacggg 780

aggaatctga cgctcccacg gtgcagaagt ctctgagtta cactgcggct ggactcttcg	840
cgaagactcg cgctcgtcagt actcttgcat tggctagagg agggactcca gtggcagtgc	900
tcgctcctcag actggaagtt aaactcaagg cccaggaaaag agcttttagac tctgcagcgc	960
ccactttcct cctggagcag cagctgtggg gagtggagtt gctgcccagt agccttcaag	1020
ctggtctagt ctcccaccga gaacttgact cttcatcctc tgggcctctg agcgttcaga	1080
gcttaggtaa tttcaaggta gtttcctatc tcctgaaccc ttctacctg gactaccttc	1140
cccagttagg gctgcgctgt cagagcagcg ctggaggtgg ccagtttgtg ggtttccgaa	1200
cactaacccc agagagctgc tatctttctg aagatggttg tcaccctcag ccgttgccgg	1260
cagagatgtc ggcaaccgcc tggagaaggt gtccgcctct ctctacagaa ggcctgccgg	1320
aatccacca ccttcgtatg aaacggctag aattcctcca ggctaacaaa gggcaagagt	1380
taccacccc tgaccaagat aatggctatc atagcctgga ggaggaacat aaccttctcc	1440
ggatggaccc acaacattgc acagataacc cagcacaggc ggtgtcccct gctgcagaca	1500
ggccggagcc cactgagaaa aaaccagaat tggtgattca agaagtttca cagagcccc	1560
aggaagcag tctgttttgt gaattaccg tgyaaaaaga atgtgaagag gaccacacta	1620
atgcaactga cctctcagat agaggagaga gccttcctgt ttctaccaga ccagtttgta	1680
gcaacaaact gatagattat attttgggag gcgccccag tgacttgga gccagctctg	1740
attctgaaag tgaggattgg ggcgaggaac ctgaggacga tggctttgat agcgtggct	1800
ccctgtctga atcagacgtg gaacaggact cgggaaggcct tcacctttgg aactctttcc	1860
acagtgtaga tccttacaaa ccccaaaact ttacagccac gattcagacg gctgccagaa	1920
ttgccccag agaccatca gattcagga catcctggtc tggcagctgt ggtgtaggga	1980
gctgtcagga gggacccctt ccggagaccc ccgaccatag ttccggggag gaagatgact	2040
gggaaccgag tgcagatgaa gcagagaatc ttaaattgtg gaactcttcc tgtcattctg	2100
aggacccta caacctttta aattttaagg ctcttttca accgtcaggg aagaattgga	2160
aaggccgtca ggactcaaag gcctcttctg aggtcacagt ggccttctct gccatcata	2220
ccttactttc ttgtaaggcc cagctgttag agagccaaga agataattgt ccaggctgtg	2280
ggctgggtga ggctcttgct ggagaaagat acacccatat caagagaaaa aaggtaacct	2340
tcctggaaga agttactgag tattatataa gtggtgatga ggatcgcaaa ggaccatggg	2400
aagaatttgc aagggatgga tgcaggttcc agaaacgaat tcaagaaaca gaagttgcca	2460

ttggctactg cttggccttt gagcacagag aaaaaatgtt taatagactg aggatcgagt	2520
caaaggactt actgttgtac agcaatgtta agaagtgaac agcctgcaac ccggtgcccac	2580
tctgtctctt acttgagagt ttcccttaaa aacaaacact ggcagctgtc cttggacatg	2640
tttttaaaga aacaacttgt atctagagat gcagtttgat tatttttggg taatgtgtct	2700
cattagaaac accaactccg ataatgaaga atctcttata tgtaatcctc tcttttccta	2760
tttagttgga tgtgggtttt gtctttttga gagggctctca ctgcataatt ctgtttggcc	2820
taggtctatg tatgtagacc aggttggcct tgaagttggt atttccttgc ctctgtttcc	2880
tgtgccacca tgcccagctg gaagtgtttt taaatatcct ctgcttacct ggggtgagag	2940
tttaattttg cactttcaaa acgtttcttc tggaggcagg ggctggtctg gtttacatac	3000
aggcttcagg ccagctaggg ctatgtggtg agacctagtc ttagaggaca aacagaacaa	3060
aacagtcagg ttactgtgga aactgaggca ggaggatagg aaggccagg tatgcctgga	3120
actcagtga ctctgaactc aaggccagca tggggagtgt agcaagacct ttttactctc	3180
agaatggaaa aggaagctgg ggatatagct cggtagcaga ggcccctgcc tacatgtgca	3240
aggctcctggg ttcagtcctc agtactgcaa atagaaagaa aaaacattgt cttggataac	3300
tataagggtt aagcctcata gtcagttcta actcaaatta tgcattgcatt gagttcttgt	3360
gtgctttttc tgttctaaaa ttaatgggct ttatgggttt tgtttttgta tgtttttatg	3420
tctgttatat tttgaggtag gggattgagg cagggctctca ctgtggcctt gagctcatgg	3480
cagttttcct gcttcaactg agtgttttgg tttgtttgtg tttgtgtttt tttactttca	3540
tagatttgac ttaatgaagg caaaaacctg ttatcaacct aaaagacatt gatgtgtcac	3600
ttcagtgggt gattttctcc ctcttttttt ttttccccca gagctgagga ccaaaccag	3660
ggctttgcac ttgctaggca agcgtcttac cactgagcta aatccccaaa ccaccccccc	3720
cccttttctt tttttaaaga catggtctta tatagtctag gctggcctta aactcattac	3780
ttagccaagg atggctttga aagatcctcc tgcctcttg tttggcttgc acatggcatg	3840
tgccatacat ccagattttt ctctgtatct aggtcttttt aagatatctc caaggactgc	3900
ccacaaatcc acagtgcagt actttcttga ctgggaaagc ggggttggtg tgcttttcaa	3960
aggcacacac cattatgccc agctggtctg ccaaacttaa catatttggg ttctgtgcaa	4020
actgtccatt tgggaagggt ctgtgtgttg tagtttcagt tgaatgtggc tctctgtagc	4080
tttcaagaat gggtagaaat cataaagcac tcttaagtaa tcattgcatt gtagacattt	4140
ttttttttta actagggggg atttgggaga catgtcagat attcactttt gttttatgtg	4200

tcttaaaacc agtggtactt acaccctgcc tcagcactgg cacttttcaa acctgtcttg	4260
gagacactgt aaacttggat ggtgcagttc tgggttttca tgtgtaaaat gtcaactaca	4320
aaggtaata tccaggtttg ttgtgttcta ccttatgtag agagaagcaa agcagaaagg	4380
gcagatagag cagccagaaa gtgctagtgt ccccccaaa gcgtgcttct agatagtgtg	4440
tggatcaggt gtgcttggtt tgttcagtta gcgtcacctg ttgtgcatgg ttgaggtaat	4500
gtgttaccag ttcttttagtg gttacatgca caaaagagag gacctctgag tcgggtgtgg	4560
gatgagcttt ccagacctgg cagggtaaac tacctcagtt tataatctcc ctggttattt	4620
ccgtttgatg tgatctaagg tctgcctcag tggatgatgt gttcatccac acacaagggt	4680
agtaagagtg cacgaccaga aacgttggtc ttatttttga gaaccccat ttctgtgtat	4740
tttatgcacc tgcctttagt gaactocaga gtgcattaaa gagtctgggt tagtgccgtg	4800
ggaatgggct agtttagaag ctatgtttgg aaagcaggca agttgacttt aggaagaaaa	4860
gctgtgacag tgtgtagaca tttcttttaa accggactgc agcttaacaa cacttgattt	4920
cagatgatta ggtttttggt tctgagaccc agcacctgta tatttaaaaa ttgttccaga	4980
ttacaccttc actatcaaata gagtaaatga ctcatgcctg cagacatgtc ctgatggtgg	5040
caagaacaga aggatctttg actgaaggag aaaaactgtc attgtcatcc cagccccag	5100
gaaagaacac ctccaaggca ggcaggcagg caggcaggca tgggtggttct agttgaatac	5160
acattcaagt cttgcagtgg tgcttttagat ctgtgtagca tgtgaggctc tgtacagggtg	5220
ggggccacac ttctgagggc tgaaatgtgg caacccttta tctaacttga aatcaaaacc	5280
gtcaaatttt attttttata atttaagaaa gagttgggga atgacatttt ttgagttggc	5340
cttttcagct cagtcatttt acgtgtaacg tggagatttg atagctcaga ttatatttgt	5400
atataattat taactaatct gtaaattgta ataaatatat ttgcaattat taaaaaaaaa	5460
aaaaaaaa	5468

<210> 4
 <211> 698
 <212> PRT
 <213> Mus musculus

<400> 4

Met	Glu	Thr	Gly	Thr	His	Arg	Ala	Arg	Lys	Arg	Pro	Gly	Pro	Arg	Leu
1				5					10					15	

Gly Ser Trp Phe Arg Leu Pro Phe Leu Arg Arg Ser His Ala Cys Ser
20 25 30

Ser Glu Phe Pro Pro Pro Ser Ser Arg Gln Asn Pro Gly Asn Ser Ala
35 40 45

Leu Pro Glu Arg Arg Thr Arg Tyr Trp Thr Lys Leu Leu Ser Gln Leu
50 55 60

Leu Ala Leu Leu Pro Ser Leu Phe Gln Lys Leu Leu Leu Trp Ser Gln
65 70 75 80

Leu Ser Gly Gly Leu Ile Pro Thr Arg Trp Leu Asp Phe Ala Ala Ser
85 90 95

Tyr Ser Ala Leu Arg Ala Ser Arg Gly Arg Glu Glu Ser Asp Ala Pro
100 105 110

Thr Val Gln Lys Ser Leu Ser Tyr Thr Ala Ala Gly Leu Phe Ala Lys
115 120 125

Thr Arg Val Val Ser Thr Leu Ala Leu Ala Arg Gly Gly Thr Pro Val
130 135 140

Ala Val Leu Val Leu Arg Leu Glu Val Lys Leu Lys Ala Gln Glu Arg
145 150 155 160

Ala Leu Asp Ser Ala Ala Pro Thr Phe Leu Leu Glu Gln Gln Leu Trp
165 170 175

Gly Val Glu Leu Leu Pro Ser Ser Leu Gln Ala Gly Leu Val Ser His
180 185 190

Arg Glu Leu Asp Ser Ser Ser Ser Gly Pro Leu Ser Val Gln Ser Leu
195 200 205

Gly Asn Phe Lys Val Val Ser Tyr Leu Leu Asn Pro Ser Tyr Leu Asp
210 215 220

Tyr Leu Pro Gln Leu Gly Leu Arg Cys Gln Ser Ser Ala Gly Gly Gly
225 230 235 240

Gln Phe Val Gly Phe Arg Thr Leu Thr Pro Glu Ser Cys Tyr Leu Ser

	245		250		255
Glu Asp Gly Cys His Pro Gln Pro Leu Arg Ala Glu Met Ser Ala Thr	260	265	270		
Ala Trp Arg Arg Cys Pro Pro Leu Ser Thr Glu Gly Leu Pro Glu Ile	275	280	285		
His His Arg Arg Met Arg Trp Leu Val Phe Leu Gln Pro Asn Gln Gly	290	295	300		
Gln Asp Leu Pro Thr Leu Asp Gln Asp Asn Gly Tyr His Ser Leu Glu	305	310	315	320	
Glu Glu His Asn Leu Leu Arg Met Asp Pro Gln His Cys Thr Asp Asn	325	330	335		
Pro Ala Gln Ala Val Ser Pro Ala Ala Asp Arg Pro Glu Pro Thr Glu	340	345	350		
Lys Lys Pro Glu Leu Val Ile Gln Glu Val Ser Gln Ser Pro Gln Gly	355	360	365		
Ser Ser Leu Phe Cys Glu Leu Pro Val Glu Lys Glu Cys Glu Glu Asp	370	375	380		
His Thr Asn Ala Thr Asp Leu Ser Asp Arg Gly Glu Ser Leu Pro Val	385	390	395	400	
Ser Thr Arg Pro Val Cys Ser Asn Lys Leu Ile Asp Tyr Ile Leu Gly	405	410	415		
Gly Ala Pro Ser Asp Leu Glu Ala Ser Ser Asp Ser Glu Ser Glu Asp	420	425	430		
Trp Gly Glu Glu Pro Glu Asp Asp Gly Phe Asp Ser Asp Gly Ser Leu	435	440	445		
Ser Glu Ser Asp Val Glu Gln Asp Ser Glu Gly Leu His Leu Trp Asn	450	455	460		
Ser Phe His Ser Val Asp Pro Tyr Lys Pro Gln Asn Phe Thr Ala Thr	465	470	475	480	

Ile Gln Thr Ala Ala Arg Ile Ala Pro Arg Asp Pro Ser Asp Ser Gly
485 490 495

Thr Ser Trp Ser Gly Ser Cys Gly Val Gly Ser Cys Gln Glu Gly Pro
500 505 510

Leu Pro Glu Thr Pro Asp His Ser Ser Gly Glu Glu Asp Asp Trp Glu
515 520 525

Pro Ser Ala Asp Glu Ala Glu Asn Leu Lys Leu Trp Asn Ser Phe Cys
530 535 540

His Ser Glu Asp Pro Tyr Asn Leu Leu Asn Phe Lys Ala Pro Phe Gln
545 550 555 560

Pro Ser Gly Lys Asn Trp Lys Gly Arg Gln Asp Ser Lys Ala Ser Ser
565 570 575

Glu Val Thr Val Ala Phe Ser Gly His His Thr Leu Leu Ser Cys Lys
580 585 590

Ala Gln Leu Leu Glu Ser Gln Glu Asp Asn Cys Pro Gly Cys Gly Leu
595 600 605

Gly Glu Ala Leu Ala Gly Glu Arg Tyr Thr His Ile Lys Arg Lys Lys
610 615 620

Val Thr Phe Leu Glu Glu Val Thr Glu Tyr Tyr Ile Ser Gly Asp Glu
625 630 635 640

Asp Arg Lys Gly Pro Trp Glu Glu Phe Ala Arg Asp Gly Cys Arg Phe
645 650 655

Gln Lys Arg Ile Gln Glu Thr Glu Val Ala Ile Gly Tyr Cys Leu Ala
660 665 670

Phe Glu His Arg Glu Lys Met Phe Asn Arg Leu Arg Ile Glu Ser Lys
675 680 685

Asp Leu Leu Leu Tyr Ser Asn Val Lys Lys
690 695

=> d his

(FILE 'HOME' ENTERED AT 15:36:20 ON 13 SEP 2005)

FILE 'HCAPLUS' ENTERED AT 15:36:28 ON 13 SEP 2005

L1 1 US2004142345/PN OR (US2002-408679# OR US2003-650482#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 15:37:28 ON 13 SEP 2005

FILE 'HCAPLUS' ENTERED AT 15:37:28 ON 13 SEP 2005

L2 TRA L1 1- RN : 55 TERMS

FILE 'REGISTRY' ENTERED AT 15:37:28 ON 13 SEP 2005

L3 55 SEA L2

FILE 'WPIX' ENTERED AT 15:37:34 ON 13 SEP 2005

L4 1 L1

=> b hcap;d all l1

FILE 'HCAPLUS' ENTERED AT 15:38:01 ON 13 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Sep 2005 VOL 143 ISS 12

FILE LAST UPDATED: 12 Sep 2005 (20050912/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L1 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:589132 HCAPLUS

DN 141:134040

ED Entered STN: 23 Jul 2004

TI Methods of screening test compounds using GADD34L, an eIF2alpha-specific phosphatase subunit

IN Ron, David; Jousse, Celine

PA USA

SO U.S. Pat. Appl. Publ., 30 pp.

CODEN: USXXCO

DT Patent

LA English

IC ICM C12Q001-68

ICS G01N033-53; G01N033-567

INCL 435006000; 435007200

CC 1-1 (Pharmacology)

Section cross-reference(s): 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2004142345	A1	20040722	US 2003-650482	20030828 <--

Searched by Noble Jarrell

PRAI US 2002-408679P P 20020906 <--

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004142345	ICM	C12Q001-68
	ICS	G01N033-53; G01N033-567
	INCL	435006000; 435007200
US 2004142345	NCL	435/006.000

<--

AB The invention is directed to methods and reagents for identifying test substances useful for the prevention or treatment of diseases involving an oxidative stress. The methods involve screening assays, including high throughput screening techniques, in which the test substances are tested for their ability to promote resistance to oxidative stress by inhibiting the activity of GADD34L, and thereby inhibiting the dephosphorylation of eIF2 α , while not causing stress.

ST GADD34L eIF2 α kinase drug screening oxidative stress; high throughput screening eIF2 α dephosphorylation inhibitor GADD34L phosphatase

IT Gene, animal
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (CAT; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (CHOP; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Proteins
 RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study)
 (GADD34, -Like (GADD34L); methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT mRNA
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (GADD34L; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Gene, animal
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (Integrated Stress Response target; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Ischemia
 (cardiac; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Nervous system, disease
 (degeneration; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Oxidative stress, biological
 (diseases involving; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT High throughput screening
 (drug; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Drug screening
 (high throughput; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Nucleic acid hybridization
 (in situ; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Kidney, disease
 (injury; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Heart, disease
 Kidney, disease
 Nerve, disease
 (ischemia; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT Gene, animal

RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (luc; methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Autoimmune disease
 DNA sequences
 Dephosphorylation, biological
 Drug screening
 Human
 Immunoassay
 Northern blot hybridization
 Protein sequences
 (methods of screening test compds. using GADD34L, an eIF2alpha-specific
 phosphatase subunit)

IT Ischemia
 (neuronal; methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Phosphorylation, biological
 (protein; methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Toxins
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (renal damage induced by; methods of screening test compds. using
 GADD34L, an eIF2alpha-specific phosphatase subunit)

IT Injury
 Ischemia
 (renal; methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stress-induced, 1, c; methods of screening test compds. using GADD34L,
 an eIF2alpha-specific phosphatase subunit)

IT Antibodies and Immunoglobulins
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (to phosphorylated eIF2 α ; methods of screening test compds. using
 GADD34L, an eIF2alpha-specific phosphatase subunit)

IT 9013-05-2D, Phosphatase, eIF2alpha-specific subunit (GADD34L)
 82249-72-7, EIF2 α kinase
 RL: ARU (Analytical role, unclassified); BSU (Biological study,
 unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological
 study)
 (methods of screening test compds. using GADD34L, an eIF2alpha-specific
 phosphatase subunit)

IT 139814-82-7, GenBank L00039 140289-54-9, GenBank M12481 150948-02-0,
 GenBank L15447 162197-23-1, GenBank D31863 178350-54-4, GenBank W90900
 183046-65-3, GenBank AA111463 183265-10-3, GenBank D87990 187578-48-9,
 GenBank AA259342 189203-30-3, GenBank U83148 189869-11-2, GenBank
 D86527 197614-27-0, GenBank AA612483 200785-26-8, GenBank AA684508
 201592-41-8, GenBank U63387 205560-99-2, GenBank AA866971 206018-51-1,
 GenBank AA881202 212429-53-3, GenBank AB014494 219900-69-3, GenBank
 AF063095 239345-32-5, GenBank AI839392 239717-83-0, GenBank AI845538
 239720-42-4, GenBank AI845798 239745-83-6, GenBank AI848343
 239773-54-7, GenBank AI851163 245142-65-8, GenBank AW120711
 245145-64-6, GenBank AW120976 245154-27-2, GenBank AW121840
 245166-12-5, GenBank AW123026 245181-02-6, GenBank AW124530
 245192-02-3, GenBank AW125634 384476-04-4, GenBank M94087 389183-14-6,
 GenBank J04103 389375-15-9, GenBank AA049696 389392-18-1, GenBank
 AA096870 389434-31-5, GenBank AA213167 390638-13-8, GenBank AK027650
 391557-92-9, GenBank U19118 391772-30-8, GenBank U40930 391791-12-1,
 GenBank U28423 391793-41-2, GenBank W84014 391807-41-3, GenBank
 AA0050417 391831-23-5, GenBank AA208877
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (methods of screening test compds. using GADD34L, an eIF2alpha-specific
 phosphatase subunit)

IT 56-86-0, L-Glutamic acid, biological studies 11089-65-9, Tunicamycin
 15502-74-6, Arsenite

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

IT 725915-01-5 725915-03-7 725915-04-8 725915-05-9 725915-06-0
726439-38-9 726439-39-0

RL: PRP (Properties)

(unclaimed nucleotide sequence; methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

IT 725915-02-6 725915-08-2

RL: PRP (Properties)

(unclaimed protein sequence; methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

IT 725915-07-1

RL: PRP (Properties)

(unclaimed sequence; methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

=> b wpix;d all 14

FILE 'WPIX' ENTERED AT 15:38:05 ON 13 SEP 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 12 SEP 2005 <20050912/UP>
MOST RECENT DERWENT UPDATE: 200558 <200558/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
PLEASE CHECK:
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/>
FOR DETAILS. <<<

'BIX BI,ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN

AN 2004-552556 [53] WPIX

DNN N2004-437171 DNC C2004-202196

TI Screening test substances for preventing or treating disease involving
oxidative stress, by testing test substances for its ability to inhibit
activity of GADD34L and identifying test substance that inhibits activity
of GADD34L.

DC B04 D16 S03

IN JOUSSE, C; RON, D

PA (JOUS-I) JOUSSE C; (ROND-I) RON D

CYC 1

PI US 2004142345 A1 20040722 (200453)* 30 C12Q001-68 <--

ADT US 2004142345 A1 Provisional US 2002-408679P 20020906, US
2003-650482 20030828

PRAI US 2002-408679P 20020906; US 2003-650482
20030828

IC ICM C12Q001-68

ICS G01N033-53; G01N033-567

AB US2004142345 A UPAB: 20040818

NOVELTY - Screening (M1) several test substances for preventing or treating disease involving an oxidative stress, involves testing the test substances for its ability to inhibit the activity of GADD34L and identifying the test substance which inhibits the activity of GADD34L, thus to identify a test substance useful as a preventive or therapeutic agent for a disease involving an oxidative stress.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) identifying (M2) a test substance useful for preventing or treating a disease involving an oxidative stress, involves testing a test substance for its ability to inhibit the activity of GADD34L, thus to determine whether the substance promotes resistance to cell stress, and to identify the substance as a preventive or therapeutic agent for a disease involving an oxidative stress; and

(2) preventing or treating (M3) a disease involving an oxidative stress in a patient in need of such treatment, involves administering to the patient a GADD34L inhibitor identified for its ability to promote resistance to cell stress while not causing stress.

ACTIVITY - Cardiant; Vasotropic; Nephrotropic; Immunosuppressive; Neuroprotective. No supporting data is given.

MECHANISM OF ACTION - Inhibitor of GADD34L protein (claimed).

USE - (M1) is useful for screening several test substances for preventing or treating disease involving an oxidative stress. (M3) is useful for preventing or treating a disease involving an oxidative stress in a patient in need of such treatment. The disease includes neuronal ischemia, heart ischemia, renal damage induced by ischemia or toxins, autoimmune disease, or neurodegenerative disorder (claimed).

DESCRIPTION OF DRAWING(S) - The figure shows inhibition of endogenous GADD34L protects cells against oxidative toxicity.

Dwg.6/7

FS CPI EPI

FA AB; GI

MC CPI: B04-E01; B04-E03B; B04-E12; B04-G01; B04-N02; B10-B02J; B11-C07A;
B11-C08E; B12-K04; B12-K04E; B14-F01; B14-F02; B14-F02D; B14-G02;
B14-J01; B14-L06; B14-N10; D05-H09; D05-H11; D05-H12A; D05-H12D6;
D05-H13

EPI: S03-E14A1; S03-E14H4

=> b home

FILE 'HOME' ENTERED AT 15:38:09 ON 13 SEP 2005

=>

=> b reg

FILE 'REGISTRY' ENTERED AT 07:57:29 ON 14 SEP 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 12 SEP 2005 HIGHEST RN 862971-50-4
 DICTIONARY FILE UPDATES: 12 SEP 2005 HIGHEST RN 862971-50-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sqide l32 tot

L32 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 725915-08-2 REGISTRY
 CN 11: PN: US20040142345 FIGURE: 3 unclaimed protein (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE
 SQL 713

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2004142345
	unclaimed
	FIG 3

```
SEQ      1 MEPGTGGSRK RLGPRAGFRF WPPFFPRRSQ AGSSKFPTPL GPENSGNPTL
      51 LSSAQPETRV SYWTKLLSQL LAPLPGLLQK VLIWSQLFGG MFPTRWLDFA
     101 GVYSALRALK GREKPAAPTA QKSLSSLQLD SSDPSVTSPL DWLEEGIHQW
     151 YSPDCLKLEL KAKGSALDPA AQAFLLQQL WGVELLPSSL QSRLYSNREL
     201 GSSPSGPLNI QRIDNFSVVS YLLNPSYLDC FPRLEVSYQN SDGNSEVVGF
     251 QTLTPRESSCL REDHCHPQPL SAELIPASWQ GCPPLSTEGE PEIHHLRMKR
     301 LEFLQQANKG QDLPTPDQDN GYHSLEEEHS LLRMDPKHCR DNPTQFVPAA
     351 GDIPGNTQES TEEKIELLTT EVPLALEEES PSEGCPSEI PMEKEPGEGR
     401 ISVVDYSYLE GDLPIARP A CSNKLIDYIL GGASSDLETS SDPEGEDWDE
     451 EAEDDGFDSD SSLSDSDLEQ DPEGLHLWNS FCSVDPYNPQ NFTATIQTAA
     501 RIVPEEPSDS EKDLGKSDL ENSSQSGSLP ETPEHSSGEE DDWESSADEA
     551 ESLKLWNSFC NSDDPYNPLN FKAPFQTSGE NEKGCRRDST PSESIVAISE
     601 CHTLLSCKVQ LLGSQESECP DSVQRDVLGS GRHSHVKKRK VTFLEEVTEY
```

651 YISGDEDRKG PWEFFARDGC RFQKRIQETE DAIGYCLTFE HRERMFNRLQ
701 GTCFKGLNVL KQC

****RELATED SEQUENCES AVAILABLE WITH SEQLINK****

MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: PRP (Properties)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L32 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN
RN 725915-07-1 REGISTRY
CN 9: PN: US20040142345 FIGURE: 2 unclaimed sequence (9CI) (CA INDEX NAME)
FS NUCLEIC ACID SEQUENCE
SQL 2942
NA 732 a 739 c 725 g 746 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2004142345
	unclaimed
	FIGURE 2

```

SEQ      1 attttgggct tcgtttccac cgcaccagcc ggccctacca gtccttccgg
51  tatcgcggttg ctcaaggggct tttcaaccct ctgtcagtcg gaaaaccatc
101 gccgaggccg tgggggggact cctatccatg gtgttgaagc gtcgagccga
151 ctagggaacc tccttccccc ccaggatgga agtcgcatca gtcgccgctt
201 attgcgcggg ctgtttcttc ctgtgttctg ccgcccgctg ccgcattcgc
251 tgccctctgt ggctttttct ctggctcgaa gatcggcctg gagcagcgac
301 gccaccgctg ggcaaggccg agactctgta ggcttcctcc gaatcccgtc
351 gacctccagc cgctgagcgc cgcggcccta cctgagagac tgtcaagaaa
401 aaggagatgg agccggggac aggcggatcg cggaaacggc ttggccctcg
451 ggcgggcttc cggttctggc cacccttttt ccctcggcga tcgcaagcag
501 gctcttctaa gttcccgacg cctcttggcc cggaaaactc cgggaacccc
551 aactgctttt cctctgcccc gcccagagact cgggtcagtt actggacgaa
601 actgctctcc cagctccttg cgcgctccc cggattgctt cagaagggtg
651 taattttggg ccaacttttc ggtggaatgt ttccgaccag atggctagat
701 tttgctggag tctacagcgc cctgagagcc ctgaagggaac gggagaaacc
751 agccgcccc cagcgcgaga aatctttgag ttcgctgcag ctcgactcct
801 cagacccctc ggtcaccagt ccccttgatt ggctagagga ggggatccac
851 tggcaatact cgcgccaga cctaaaattg gagcttaagg ccaagggaag
901 tgctttggac cctgcagcac aggcctttct cttagagcag cagctgtggg
951 gagtggagct gttgcccagt agccttcaat cccgtctgta ctctaaccgg
1001 gaacttggtt cttcgccctc tgggcctcta aacattcaac gcatagacaa
1051 tttcagtggt gtatcctatt tgctgaaccc ttccctacct gactgcttct
1101 ctaggctaga agtcagctat cagaacagtg atggaatag cgaggtagtc
1151 ggcttccaga cactaacccc agagagcagc tgccctgagag aggaccattg
1201 tcatccccag ccgctgagtg cagaactcat tccggcctcg tggcagggat
1251 gtccacctct ttctacggaa ggcctaccag aaattcacca tcttcgcatg
1301 aaacggctgg aattccttca acaggctaac aaggggcaag atttaccac
1351 ccctgaccag gataatggct accacagcct ggaggaggaa cacagccttc
1401 tccggatgga tccaaaacac tgcagagata acccaacaca gtttgttctt
1451 gctgctggag acattccttg aaacaccagc gaatccactg aagaaaaaat
1501 agaattatta actacagagg ttccacttgc tttggaagaa gagagccctt
1551 ctgagggctg tccatctagt gagataccta tggaaaagga gcctggagag
1601 ggcgaataaa gtgtagttga ttactcatac ctagaagggt accttcccat
1651 ttctgccaga ccagcttgta gtaacaaact gatagattat attttgggag
1701 gtgcatccag tgacctggaa acaagttctg atccagaagg tgaggattgg
1751 gatgagggaag ctgaggatga tggttttgat agtgatagct cactgtcaga
1801 ctcagacctt gaacaagacc ctgaagggtt tcacctttgg aactctttct

```

```

1851 gcagtgtaga tccttataat ccccagaact ttacagcaac aattcagact
1901 gctgccagaa ttgttcctga agagccttct gattcagaga aggatttgct
1951 tggcaagtct gatctagaga attcctccca gtctggaagc cttcctgaga
2001 cccctgagca tagttctggg gaggaagatg actgggaatc tagtgagat
2051 gaagcagaga gtctcaaaact gtggaactca ttctgtaatt ctgatgaccc
2101 ctacaaccct ttaaatttta aggtccttt tcaaacaatca ggggaaaatg
2151 agaaaggctg tcgtgactca aagaccccat ctgagtcctat tgtggccatt
2201 tctgagtgtc acaccttact ttcttgtaag gtgcagctgt tggggagcca
2251 agaaagtga tgtccagact cggtagacgc tgacgttctt tctggaggaa
2301 gacacacaca tgtcaaaaga aaaaaggtaa ccttccttga agaagtact
2351 gagtattata taagtgggtga tgaggatcgc aaaggacat gggagaatt
2401 tgcaagggat ggatgcaggt tccagaaacg aattcaagaa acagaagatg
2451 ctattggata ttgcttgaca tttgaacaca gagaaagaat gtttaataga
2501 ctccagggaa catgcttcaa aggaactaat gttctcaagc aatgttgagt
2551 tggcagcctg tagtcctagc tagcatacac tacctcttac ctgagagggtg
2601 tcttttaaaa acaaatcttg gcagctgtcc tttgacattt ttttttttag
2651 aggaatgta acttgatct agtttaattt ttttttttgc aacatatccc
2701 actcagaaac attcaggttt gaagccagcc ctgataatga aggatgaact
2751 agtgtgattt ctaatcctcc cttttttgat ttagttggat gtgcttttaa
2801 atgtcctttg cctgcagatg gtggaagggt gacctttttg agttgtcatt
2851 ttgcactttc aaaaacttatt ttcttggaac acaatattta tagggcttaa
2901 agcccatttt catttctaatt ctaaattatg tgtgcctatc tg

```

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L32 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN

RN 725915-02-6 REGISTRY

CN 2: PN: US20040142345 FIGURE: 5 unclaimed protein (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE

SQL 698

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2004142345
	unclaimed
	FIG 5

```

SEQ      1 METGTHRARK  RGPRLGSWF  RLPFLRRSHA  CSSEFPPSS  RQNPNGNSALP
      51 ERRTRYWTKL  LSQLLALLPS  LFQKLLLSQ  LSGGLIPTRW  LDFAASYSAL
     101 RASRGREESD  APTVQKLSY  TAAGLFAKTR  VVSTLALARG  GTPVAVLVLR
     151 LEVKLKAQER  ALDSAAPTFL  LEQQLWGVEL  LPSSLQAGLV  SHRELDSSSS
     201 GPLSVQSLGN  FKVVSYLELN  SYLDYLPQLG  LRCQSSAGGG  QFVGFRITLP
     251 ESCYLSGDG  HPQPLRAEMS  ATAWRRCPP  STEGLPEIHH  RMRWLVLFLQ
     301 PNQGQDLPTL  DQDNGYHSLE  EEHNLLRMDP  QHCTDNPAQA  VSPAADRPEP
     351 TEKKPELVIQ  EVSQSPQGSS  LFCELPVEKE  CEDHTNATD  LSDRGESLPV
     401 STRPVCSNKL  IDYILGGAPS  DLEASSDSES  EDWGEEPEDD  GFDSGSLSE
     451 SDVEQDSEGL  HLWNSFHSD  PYKPQNFTAT  IQTAARIAPR  DPSDSGTSWS
     501 GSCGVGSCQE  GPLPETPDHS  SGEEDDWEPS  ADEAENLKLW  NSFCHSEDPY
     551 NLLNFKAPFQ  PSKKNWKGRQ  DSKASSEVTV  AFSGHHTLLS  CKAQLLESQE
     601 DNCPGCGLGE  ALAGERYTHI  KRKKVTFLEE  VTEYYISGDE  DRKGPWEEFA
     651 RDGCRFQKRI  QETEVAGIYC  LAFEHREKMF  NRLRIESKDL  LLYSNVKK

```

MF Unspecified

CI MAN

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA Caplus document type: Patent

RL.P Roles from patents: PRP (Properties)

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L32 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2005 ACS on STN
 RN 725915-01-5 REGISTRY
 CN 1: PN: US20040142345 FIGURE: 4 unclaimed DNA (9CI) (CA INDEX NAME)
 FS NUCLEIC ACID SEQUENCE
 SQL 5468
 NA 1321 a 1272 c 1366 g 1509 t

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2004142345
	unclaimed
	FIG 4

```

SEQ      1  cggctcctccg  tctcgccctg  cagcttcocg  gtgtgcggct  gcggccattt
51  tgagcttcgc  ttctttgcgc  cctcgccctg  caccagcca  ccctttccgc
101  cttggcgttt  cgcgcctccg  tgcggggcc  cggaacgcc  gccgtcgtct
151  ccgtgcgcgc  cgcgcgaggg  agggctctct  ctatggtgga  gcgatctcac
201  acggcctagg  acgtctcctt  ccctagccgg  gatggacct  accgcggtcg
251  ccaccgcttg  cgcggggcct  tgggcccgtc  ggtgcagcac  tcgttcgcca
301  agccgcgcgt  ctctgggcct  cctctgcgg  cgcgggaatc  ggactgcagt
351  acccactccg  tggctgggca  agcggagac  tgttagacc  tcggatccag
401  cctgcgctga  cgcgcgtgag  ctctgtctc  ctctgtctg  agaagccgcc
451  aaggaaagga  gatggagaca  ggaacgcaca  gggcccggaa  gcggcctggc
501  cctcggtcgg  gctcctgggt  ccgctgcgcc  ttcttcggc  gatcgcacgc
551  ctgctcttcg  gagttccgc  cgccttctc  tcgacaaaat  cccgggaact
601  ccgctctgcc  cgagcgtcgg  accaggtact  ggaccaaatt  gctttctcag
651  ctccctgccc  tgctccctag  cctattccag  aagctgctgc  tttggagcca
701  gctttccggg  ggctgatct  ctaccagatg  gctagatttt  gccgcaagtt
751  acagcgccct  gagagcttcg  agaggacggg  aggaatctga  cgctcccacg
801  gtgcagaagt  ctctgagtta  cactgcggct  ggactcttcg  cgaagactcg
851  cgtcgtcag  actcttgcat  tggctagagg  agggactcca  gtggcagtgc
901  tcgtcctcag  actggaagtt  aaactcaagg  cccaggaaa  agctttagac
951  tctgcagcgc  ccactttcct  cctggagcag  cagctgtggg  gagtggagtt
1001  gctgcccagt  agccttcaag  ctggtctagt  ctcccaccga  gaacttgact
1051  cttcctcctc  tgggcctctg  agcgttcaga  gcttaggtaa  tttcaaggta
1101  gtttctcttc  tcctgaacct  ttctacctg  gactaccttc  cccagtttag
1151  gctgcgctgt  cagagcagcg  ctggaggtgg  ccagtgtgtg  ggtttccgaa
1201  cactaacccc  agagagctgc  tatctttctg  aagatggttg  tcaccctcag
1251  ccgttgccgg  cagagatgtc  ggcaaccgcc  tggagaagg  gtccgcctct
1301  ctctacagaa  ggctgcggg  aaatccacca  ccttcgtatg  aaacggctag
1351  aattcctcca  ggtaacaaa  gggcaagagt  taccacccc  tgaccaagat
1401  aatggctatc  atagcctgga  ggaggaacat  aacctctctc  ggatggaccc
1451  acaacattgc  acagataacc  cagcacaggc  ggtgtccctc  gctgcagaca
1501  ggccggagcc  cactgagaaa  aaaccagaat  tggtgattca  agaagtttca
1551  cagagccccc  agggaagcag  tctgttttgt  gaattacccg  tggaaaaaga
1601  atgtgaagag  gaccacacta  atgcaactga  cctctcagat  agaggagaga
1651  gccttcctgt  ttctaccaga  ccagtgtgta  gcaacaaact  gatagattat
1701  attttgggag  gcgccccag  tgacttgga  gccagctctg  attctgaaag
1751  tgaggattgg  ggcgaggaac  ctgaggacga  tggctttgat  agcgatggct
1801  ccctgtctga  atcagacgtg  gaacaggact  cggaaaggct  tcacctttgg
1851  aactccttcc  acagtgtaga  tccttaca  ccccaaaact  ttacagccac
1901  gattcagacg  gctgccagaa  ttgccccag  agaccatca  gattcagggg
1951  catcctggtc  tggcagctgt  ggtgtaggga  gctgtcagga  gggacccctt
2001  ccgagacccc  ccgaccatag  ttccggggag  gaagatgact  gggaaccgag
2051  tgcagatgaa  gcagagaatc  ttaaattgtg  gaactcttct  tgtcattctg
2101  aggaccctta  caacctttta  aattttaagg  ctccttttca  accgtcaggg
2151  aagaattgga  aaggccgtca  ggactcaaag  gcctctctg  aggtcacagt
2201  ggcttctct  ggccatcata  ccttactttc  ttgtaaggcc  cagctgttag
2251  agagccaaga  agataattgt  ccaggctgtg  ggctgggtga  ggctcttgct
2301  ggagaaagat  acacccatat  caagagaaaa  aaggtaacct  tctggaaga

```



```

2351 agttactgag tattatataa gtggtgatga ggatcgcaaa ggaccatggg
2401 aagaatttgc aagggatgga tgcaggttcc agaaacgaat tcaagaaaca
2451 gaagttgcc aaggctactg cttggccttt gagcacagag aaaaaatgtt
2501 taatagactg aggatcgagt caaaggactt actgttgtag agcaatgtta
2551 agaagtgaac agcctgcaac ccgtgcccac tctgtctctt acttgagagt
2601 ttcccttaaa aacaaacact ggcagctgtc cttggacatg tttttaaga
2651 aacaacttgt atctagagat gcagtttgat tatttttggg taatgtgtct
2701 cattagaaac accaactccg ataataga atctcttctc tgtaatctct
2751 tcttttctta tttagttgga tgtgggtttt gtctttttga gaggtctctc
2801 ctgcataaatt ctggttggtc taggtctatg tatgtagacc aggttggcct
2851 tgaagttggt atttctctgc ctctgtttcc tgtgccacca tgcccagctg
2901 gaagtgtttt taaatatcct ctgcttacct ggggtgagag ttttaattttg
2951 cactttcaaa acgtttcttc tggaggcagg ggctggtctg gtttacatac
3001 aggtctcagg ccagctaggg ctatgtggtg agacctagtc ttagaggaca
3051 aacagaacaa aacagtcagg ttactgtgga aactgaggca ggaggtatagg
3101 aaggtccagg tatgcctgga actcagtga ctctgaactc aaggccagca
3151 gaagtgtttt ttttaacactc agaattggaaa aggaagctgg
3201 ggatatagct cggtagcaga ggcctctgcc tacatgtgca aggtctctgg
3251 ttcagtcctc agtactgcaa atagaaagaa aaaacattgt cttggataac
3301 tataaggttt aagcctcata gtctgttcta actcaaatta tgcattgcatt
3351 gagttcttgt gtgtcttttc tgttctaaaa ttaatgggct ttatgggttt
3401 tgtttttgtg tctttttatg tctgttatat tttgaggtag gggattgagg
3451 caggggtctc ctgtggcctt gagctcatgg cagttttcct gcttcaactg
3501 agtgtttttg tttgtttgtg tttgtgtttt tttactttca tagatttgac
3551 ttaatgaagg caaaaacctg ttatcaacct aaaagacatt gatgtgtcac
3601 ttcagtggtg gatttttctc ctcttttttt ttttccccca gagctgagga
3651 ccaaaccagg ggctttgcac ttgctaggca agcgtctctc cactgagcta
3701 aatccccaaa ccaccccccc cccttttctt tttttaaaga catggtctta
3751 tatagtctag gctggcctta aactcattac ttagccaagg atggctttga
3801 aagatcctcc tgtcctcttg tttggcttgc acatggcatg tgccatacat
3851 ccagattttt ctctgtatct aggtcttttt aagatatctc caaggactgc
3901 ccacaaatcc acagtgcagt actttcttga ctgggaaagc ggggttggtg
3951 tgcttttcaa aggcacacac cattatgccc agctggtctg ccaaacttaa
4001 catatttggt ttctgtgcaa actgtccatt tggaaaggtt ctgtgtgttg
4051 tagtttcagt tgaatgtggc tctctgtagc tttcaagaat gggtagaaat
4101 cataaagcac tcttaagtaa tcattgcatt gtagacattt ttttttttta
4151 actagggggt atttgggaga catgtcagat attcactttt gttttatgtg
4201 tcttaaaacc agtgttactt acacccctgc tcagcaactg cacttttcaa
4251 acctgtcttg gagacactgt aaacttggat ggtgcagttc tgggttttca
4301 tgtgtaaaat gtcaactaca aaggtcaata tccagggttg ttgtgttcta
4351 ccttatgtag agagaagcaa agcagaaagg gcagatagag cagccagaaa
4401 gtgctagtgt ccccccacaa gcgtgcttct agatagtgtg tggatcagg
4451 gtgcttggtt tgttcagtta gcgtcacctg ttgtgcattg ttgaggtaat
4501 gtgttaccag ttcttttagt gttacatgca caaaagagag gacctctgag
4551 tgggtgtgtg gatgagcttt ccagacctgg cagggtaaac tacctcagtt
4601 tataatctcc ctggttattt ccgtttgatg tgatctaagg tctgcctcag
4651 tgggtgatgat gttcatccac acacaagggt agtaagagtg cacgaccaga
4701 aacgttggtc ttatttttga gaacccccat ttctgtgtat tttatgcacc
4751 tgcttttagt gaactccaga gtgcattaaa gactctggtt tagtgccgtg
4801 ggaatgggct agtttagaag ctatgttttg aaagcaggca agttgacttt
4851 aggaagaaaa gctgtgacag tgtgtagaca tttcttttaa accggactgc
4901 agcttaacaa cacttgattt cagatgatta ggtttttggt tctgagacc
4951 agcacctgta tatttaaaaa ttgttccaga ttacaccttc actatacaat
5001 gagtaaatga ctcatgcctg cagacatgtc ctgatggtgg caagaacaga
5051 aggatctttg actgaaggag aaaaactgtc attgtcatcc cagccccag
5101 gaaagaacac ctccaaggca ggcaggcagg caggcaggca tgggtggtct
5151 agttgaatac acattcaagt cttgcagtgg tgcttttagat ctgtgtagca
5201 tgtgaggctc tgtacagggt ggggccacac ttctgagggc tgaaatgtgg
5251 caacctttta tctaacttga aatcaaaacc gtcaaatatt attttttata
5301 atttaagaaa gagttgggga atgacatttt ttgagttggc cttttcagct
5351 cagtcatttt acgtgtaacg tggagatttg atagctcaga ttataattgt
5401 atataattat taactaatct gtaaattgta ataaatatat ttgcaattat
5451 taaaaaaaaa aaaaaaaaaa

```

MF Unspecified
CI MAN
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
 DT.CA Cplus document type: Patent
 RL.P Roles from patents: PRP (Properties)
 1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his full

(FILE 'HOME' ENTERED AT 07:28:25 ON 14 SEP 2005)

FILE 'HCAPLUS' ENTERED AT 07:28:58 ON 14 SEP 2005

L1 1 SEA ABB=ON PLU=ON US2004142345/PN OR (US2002-408679# OR
 US2003-650482#)/AP,PRN

FILE 'REGISTRY' ENTERED AT 07:29:09 ON 14 SEP 2005

FILE 'HCAPLUS' ENTERED AT 07:29:09 ON 14 SEP 2005

L2 TRA L1 1- RN : 55 TERMS

FILE 'REGISTRY' ENTERED AT 07:29:10 ON 14 SEP 2005

L3 55 SEA ABB=ON PLU=ON L2
 L4 1 SEA ABB=ON PLU=ON L3 AND 9013-05-2
 L5 23 SEA ABB=ON PLU=ON (EIF2A OR EIF2(W)ALPHA)/CNS
 L6 0 SEA ABB=ON PLU=ON L5 AND 82249-72-7
 L7 1 SEA ABB=ON PLU=ON 82249-72-7
 L8 77 SEA ABB=ON PLU=ON (EIF(W)(2A OR 2 (W)ALPHA))/CNS
 L9 43 SEA ABB=ON PLU=ON ((EUKARYOTIC INITIATION FACTOR OR INITIATIO
 N (W)FACTOR) (W) (2A OR 2 (W)ALPHA))/CNS
 L10 77 SEA ABB=ON PLU=ON (L7 OR L8)
 L11 137 SEA ABB=ON PLU=ON (L5 OR L9 OR L10)
 L12 1 SEA ABB=ON PLU=ON L11 AND (PHOSPHATASE? OR GADD34L OR GADD
 (1A)(34L OR 34 (1A)L) OR GADD34 (1A)L)

FILE 'HCAPLUS' ENTERED AT 07:41:04 ON 14 SEP 2005

L13 1374 SEA ABB=ON PLU=ON L11
 L14 2218 SEA ABB=ON PLU=ON EIF2A OR EIF2(W)ALPHA OR (EIF OR
 EUKARYOTIC INITIATION FACTOR OR INITIATION (W)FACTOR) (W) (2.ALPH
 A. OR 2 (W)ALPHA OR 2)
 L15 2934 SEA ABB=ON PLU=ON (L13 OR L14)
 E RON D/AU
 L16 117 SEA ABB=ON PLU=ON ("RON D"/AU OR "RON DAVID"/AU)
 E JOUSSE C/AU
 L17 22 SEA ABB=ON PLU=ON ("JOUSSE C"/AU OR "JOUSSE CELINE"/AU)
 L18 24509 SEA ABB=ON PLU=ON (NYU OR NEW (W)YORK (W)UNIV?)/CS,PA
 D BIB
 L19 57 SEA ABB=ON PLU=ON L15 AND (L16 OR L17 OR L18)
 D QUE L12
 L20 1 SEA ABB=ON PLU=ON L15 (L) (GADD34L OR GADD (1A)(34L OR 34
 (1A)L) OR GADD34 (1A)L)
 D SCA
 L21 1 SEA ABB=ON PLU=ON L20 AND L19
 L22 39104 SEA ABB=ON PLU=ON (DRUG SCREENING+OLD OR HIGH THROUGHPUT
 SCREENING)/CT
 L23 2877 SEA ABB=ON PLU=ON L15 NOT L19
 L24 86 SEA ABB=ON PLU=ON L23 AND L22
 L25 137 SEA ABB=ON PLU=ON L15 (L) ?PHOSPHATAS?
 L26 2 SEA ABB=ON PLU=ON L24 AND L25

FILE 'REGISTRY' ENTERED AT 07:55:05 ON 14 SEP 2005

L27 QUE ABB=ON PLU=ON SQL=2942
 L28 QUE ABB=ON PLU=ON SQL=713
 L29 QUE ABB=ON PLU=ON SQL=5468
 L30 QUE ABB=ON PLU=ON SQL=698
 L31 5 SEA ABB=ON PLU=ON L3 AND (L27 OR L28 OR L29 OR L30)
 L32 4 SEA ABB=ON PLU=ON L31 NOT NT2RP3002770

FILE 'HCAPLUS' ENTERED AT 07:58:42 ON 14 SEP 2005
 L33 1 SEA ABB=ON PLU=ON L32
 L34 1 SEA ABB=ON PLU=ON GADD34L OR GADD(1A) (34L OR 34 (1A)L) OR
 GADD34 (1A)L
 L35 1 SEA ABB=ON PLU=ON (L33 OR L34)
 L36 1 SEA ABB=ON PLU=ON (L35 OR L21)

FILE 'USPATFULL, USPAT2' ENTERED AT 08:00:38 ON 14 SEP 2005
 L37 1 SEA ABB=ON PLU=ON L31

FILE 'HCAOLD' ENTERED AT 08:01:03 ON 14 SEP 2005
 L38 0 SEA ABB=ON PLU=ON L31
 L39 0 SEA ABB=ON PLU=ON GADD34L OR GADD(1A) (34L OR 34 (1A)L) OR
 GADD34 (1A)L

=> b hcap

FILE 'HCAPLUS' ENTERED AT 08:01:29 ON 14 SEP 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2005 VOL 143 ISS 12
 FILE LAST UPDATED: 13 Sep 2005 (20050913/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 136 tot

L36 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:589132 HCAPLUS
 DN 141:134040
 ED Entered STN: 23 Jul 2004
 TI Methods of screening test compounds using GADD34L, an
 eIF2alpha-specific phosphatase subunit
 IN Ron, David; Jousse, Celine
 PA USA
 SO U.S. Pat. Appl. Publ., 30 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM C12Q001-68
 ICS G01N033-53; G01N033-567
 INCL 435006000; 435007200
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 15
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004142345	A1	20040722	US 2003-650482	20030828
PRAI US 2002-408679P	P	20020906		

CLASS

Searched by Noble Jarrell

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004142345	ICM	C12Q001-68
	ICS	G01N033-53; G01N033-567
	INCL	435006000; 435007200
US 2004142345	NCL	435/006.000
AB	The invention is directed to methods and reagents for identifying test substances useful for the prevention or treatment of diseases involving an oxidative stress. The methods involve screening assays, including high throughput screening techniques, in which the test substances are tested for their ability to promote resistance to oxidative stress by inhibiting the activity of GADD34L, and thereby inhibiting the dephosphorylation of eIF2 α , while not causing stress.	
ST	GADD34L eIF2 α kinase drug screening oxidative stress; high throughput screening eIF2 α dephosphorylation inhibitor GADD34L phosphatase	
IT	Gene, animal RL: ARU (Analytical role, unclassified); ANST (Analytical study) (CAT; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Gene, animal RL: BSU (Biological study, unclassified); BIOL (Biological study) (CHOP; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Proteins RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study) (GADD34, -Like (GADD34L); methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	mRNA RL: BSU (Biological study, unclassified); BIOL (Biological study) (GADD34L; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Gene, animal RL: BSU (Biological study, unclassified); BIOL (Biological study) (Integrated Stress Response target; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Ischemia (cardiac; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Nervous system, disease (degeneration; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Oxidative stress, biological (diseases involving; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	High throughput screening (drug; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Drug screening (high throughput; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Nucleic acid hybridization (in situ; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Kidney, disease (injury; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Heart, disease Kidney, disease Nerve, disease (ischemia; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)	
IT	Gene, animal	

RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (luc; methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Autoimmune disease
 DNA sequences
 Dephosphorylation, biological
 Drug screening
 Human
 Immunoassay
 Northern blot hybridization
 Protein sequences
 (methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Ischemia
 (neuronal; methods of screening test compds. using GADD34L,
 an eIF2alpha-specific phosphatase subunit)

IT Phosphorylation, biological
 (protein; methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Toxins
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (renal damage induced by; methods of screening test compds. using
 GADD34L, an eIF2alpha-specific phosphatase subunit)

IT Injury
 Ischemia
 (renal; methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stress-induced, 1, c; methods of screening test compds. using
 GADD34L, an eIF2alpha-specific phosphatase subunit)

IT Antibodies and Immunoglobulins
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (to phosphorylated eIF2 α ; methods of
 screening test compds. using GADD34L, an eIF2alpha-specific
 phosphatase subunit)

IT 9013-05-2D, Phosphatase, eIF2alpha-specific subunit (GADD34L)
 82249-72-7, EIF2 α kinase
 RL: ARU (Analytical role, unclassified); BSU (Biological study,
 unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological
 study)
 (methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT 139814-82-7, GenBank L00039 140289-54-9, GenBank M12481 150948-02-0,
 GenBank L15447 162197-23-1, GenBank D31863 178350-54-4, GenBank W90900
 183046-65-3, GenBank AA111463 183265-10-3, GenBank D87990 187578-48-9,
 GenBank AA259342 189203-30-3, GenBank U83148 189869-11-2, GenBank
 D86527 197614-27-0, GenBank AA612483 200785-26-8, GenBank AA684508
 201592-41-8, GenBank U63387 205560-99-2, GenBank AA866971 206018-51-1,
 GenBank AA881202 212429-53-3, GenBank AB014494 219900-69-3, GenBank
 AF063095 239345-32-5, GenBank AI839392 239717-83-0, GenBank AI845538
 239720-42-4, GenBank AI845798 239745-83-6, GenBank AI848343
 239773-54-7, GenBank AI851163 245142-65-8, GenBank AW120711
 245145-64-6, GenBank AW120976 245154-27-2, GenBank AW121840
 245166-12-5, GenBank AW123026 245181-02-6, GenBank AW124530
 245192-02-3, GenBank AW125634 384476-04-4, GenBank M94087 389183-14-6,
 GenBank J04103 389375-15-9, GenBank AA049696 389392-18-1, GenBank
 AA096870 389434-31-5, GenBank AA213167 390638-13-8, GenBank AK027650
 391557-92-9, GenBank U19118 391772-30-8, GenBank U40930 391791-12-1,
 GenBank U28423 391793-41-2, GenBank W84014 391807-41-3, GenBank
 AA0050417 391831-23-5, GenBank AA208877
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (methods of screening test compds. using GADD34L, an
 eIF2alpha-specific phosphatase subunit)

IT 56-86-0, L-Glutamic acid, biological studies 11089-65-9, Tunicamycin

15502-74-6, Arsenite

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

IT 725915-01-5 725915-03-7 725915-04-8 725915-05-9
725915-06-0 726439-38-9 726439-39-0

RL: PRP (Properties)

(unclaimed nucleotide sequence; methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

IT 725915-02-6 725915-08-2

RL: PRP (Properties)

(unclaimed protein sequence; methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

IT 725915-07-1

RL: PRP (Properties)

(unclaimed sequence; methods of screening test compds. using GADD34L, an eIF2alpha-specific phosphatase subunit)

=> d all hitseq hitstr l26 tot

L26 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:626521 HCAPLUS

DN 139:144971

ED Entered STN: 15 Aug 2003

TI Protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses

IN Mao, Yumin; Xie, Yi

PA Biowindow Gene Development Inc., Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 34 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

IC ICM C07K014-47

ICS C07K016-18; C12N015-10; C12N015-11; C12N015-12; C12N015-63;
C12N015-64; C07H021-00; C12P021-02

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 13

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1364785	A	20020821	CN 2001-105157	20010110
PRAI	CN 2001-105157		20010110		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
CN 1364785	ICM	C07K014-47
	ICS	C07K016-18; C12N015-10; C12N015-11; C12N015-12; C12N015-63; C12N015-64; C07H021-00; C12P021-02

AB The invention provides protein and cDNA sequences of a novel 14.63-kilodalton human protein, designated as "phosphatase 2A catalytic subunit α 14.63", which has similar expression pattern to that of known phosphatase 2A catalytic subunit α . The invention relates to expression of phosphatase 2A catalytic subunit α -like protein in E. coli BL21(DE3)plySs transfected with plasmid pET-28(+). The invention also relates to preparation of antibody against phosphatase 2A catalytic subunit α -like protein. The invention further relates to the uses of the phosphatase 2A catalytic subunit α -like protein in treatment of phosphatase 2A catalytic subunit α -related diseases.

ST phosphatase 2A catalytic subunit alpha protein cDNA sequence human

IT Immunity

(disorder, treatment of; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

IT Brain

- (fetal, phosphatase 2A catalytic subunit α -like protein cloned from; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Nucleic acid hybridization
(for detecting phosphatase 2A catalytic subunit α -like protein mRNA; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Nucleic acid amplification (method)
(for detecting phosphatase 2A catalytic subunit α -like protein nucleic acid; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Plasmid vectors
Viral vectors
(for expressing phosphatase 2A catalytic subunit α -like protein; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Diagnosis
(mol.; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Anti-AIDS agents
Anti-inflammatory agents
Antitumor agents
(phosphatase 2A catalytic subunit α -like protein as; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT mRNA
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(phosphatase 2A catalytic subunit α -like protein, tissue expression profile; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT DNA microarray technology
Drug screening
Human
Molecular cloning
Protein sequences
cDNA sequences
(protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Primers (nucleic acid)
Probes (nucleic acid)
RL: ARU (Analytical role, unclassified); BVU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Antisense nucleic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT Antibodies and Immunoglobulins
RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)
(to phosphatase 2A catalytic subunit α -like protein; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT AIDS (disease)
Blood, disease
Inflammation
Neoplasm
(treatment of; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)
- IT 569387-74-2P
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);

DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

IT 70356-43-3P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(catalytic subunit α -like protein; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

IT 569387-73-1 569387-75-3

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide sequence; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

IT 569478-48-4 569478-49-5 569478-50-8 569478-51-9 569478-52-0
569478-53-1

RL: PRP (Properties)
(unclaimed nucleotide sequence; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

IT 569353-18-0

RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

IT 70356-43-3P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(catalytic subunit α -like protein; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

RN 70356-43-3 HCAPLUS

CN Phosphatase, protein formation initiation factor IF-2 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 70356-43-3P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(catalytic subunit α -like protein; protein and cDNA sequences of 14.63-kilodalton human phosphatase 2A catalytic subunit α -like protein and their therapeutic uses)

RN 70356-43-3 HCAPLUS

CN Phosphatase, protein formation initiation factor IF-2 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L26 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:290699 HCAPLUS

DN 132:318002

ED Entered STN: 05 May 2000

TI Assay for detecting modulators of serine/threonine phosphatase activity

IN Ciaramella, Giuseppe

PA Pfizer Limited, UK; Pfizer Inc.

SO Eur. Pat. Appl., 49 pp.

CODEN: EPXXDW

DT Patent

LA English

IC ICM C12Q001-70

ICS G01N033-573
 CC 1-1 (Pharmacology)
 Section cross-reference(s): 15
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 997537	A2	20000503	EP 1999-307236	19990913
	EP 997537	A3	20040128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	GB 2342716	A1	20000419	GB 1999-17631	19990727
	GB 2342716	B2	20040512		
	CA 2280276	AA	20000314	CA 1999-2280276	19990830
	JP 2000135100	A2	20000516	JP 1999-259843	19990914
PRAI	GB 1998-20025	A	19980914		
	GB 1999-17631	A	19990727		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
EP 997537	ICM	C12Q001-70
	ICS	G01N033-573
EP 997537	ECLA	C12Q001/42; C12Q001/48B
GB 2342716	ECLA	C12Q001/18; C12Q001/48B

AB An assay method for identifying an agent that can affect the activity or expression of a nucleotide sequence or the expression product (IP) thereof is described. The assay method comprises contacting an agent with a nucleotide sequence coding for a serine/threonine phosphatase; and/or the EP thereof (i.e., a serine/threonine phosphatase); and determining whether the agent affects the activity or expression of the nucleotide sequence and/or the EP. The procedure is of use in screening antiviral agents.

ST drug screening serine threonine phosphatase modulator sequence

IT Initiation factors (protein formation)

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (Tif (translation initiation factor), eIF2 α ;
 assay for detecting modulators of serine/threonine phosphatase
 activity for virucide screening)

IT Antiviral agents

Drug screening

Protein sequences

Signal transduction, biological

cDNA sequences

(assay for detecting modulators of serine/threonine phosphatase
 activity for virucide screening)

IT Interferons

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(assay for detecting modulators of serine/threonine phosphatase
 activity for virucide screening)

IT Immunoassay

(enzyme-linked immunosorbent assay; assay for detecting modulators of serine/threonine phosphatase activity for virucide screening)

IT Gene

(expression; assay for detecting modulators of serine/threonine phosphatase activity for virucide screening)

IT 9025-75-6, Serine/threonine phosphatase

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(PP1, modulators; assay for detecting modulators of serine/threonine phosphatase activity for virucide screening)

IT 148789-74-6 191429-83-1, Protein (human clone pHu34B gene GADD34)

RL: BAC (Biological activity or effector, except adverse); BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU

(Occurrence); PROC (Process)
 (amino acid sequence; assay for detecting modulators of
 serine/threonine phosphatase activity for virucide screening)
 IT 91608-96-7, Protein kinase DAI
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological
 study, unclassified); PRP (Properties); BIOL (Biological study); OCCU
 (Occurrence); PROC (Process)
 (assay for detecting modulators of serine/threonine phosphatase
 activity for virucide screening)
 IT 148428-13-1 266331-92-4
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study); OCCU (Occurrence)
 (nucleotide sequence; assay for detecting modulators of
 serine/threonine phosphatase activity for virucide screening)
 IT 91608-96-7, Protein kinase DAI
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological
 study, unclassified); PRP (Properties); BIOL (Biological study); OCCU
 (Occurrence); PROC (Process)
 (assay for detecting modulators of serine/threonine phosphatase
 activity for virucide screening)
 RN 91608-96-7 HCAPLUS
 CN Kinase (phosphorylating), protein, DAI (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 91608-96-7, Protein kinase DAI
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological
 study, unclassified); PRP (Properties); BIOL (Biological study); OCCU
 (Occurrence); PROC (Process)
 (assay for detecting modulators of serine/threonine phosphatase
 activity for virucide screening)
 RN 91608-96-7 HCAPLUS
 CN Kinase (phosphorylating), protein, DAI (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> b uspatall
 FILE 'USPATFULL' ENTERED AT 08:02:16 ON 14 SEP 2005
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS).

FILE 'USPAT2' ENTERED AT 08:02:16 ON 14 SEP 2005
 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn l37 tot

L37 ANSWER 1 OF 1 USPATFULL on STN
 AN 2004:184462 USPATFULL
 TI Methods of screening test compounds using GADD34L, an eIF2alpha-specific
 phosphatase subunit
 IN Ron, David, New York, NY, UNITED STATES
 Jousse, Celine, Saint Genes Champanelle, FRANCE
 PI US 2004142345 A1 20040722
 AI US 2003-650482 A1 20030828 (10)
 PRAI US 2002-408679P 20020906 (60)
 DT Utility
 FS APPLICATION
 LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257
 CLMN Number of Claims: 32
 ECL Exemplary Claim: 1
 DRWN 11 Drawing Page(s)
 LN.CNT 1851
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention is directed to methods and reagents for identifying test
 substances useful for the prevention or treatment of diseases involving
 an oxidative stress. The methods involve screening assays, including
 high throughput screening techniques, in which the test substances are

tested for their ability to promote resistance to oxidative stress by inhibiting the activity of GADD34L, and thereby inhibiting the dephosphorylation of eIF2 α , while not causing stress.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 390638-13-8, GenBank AK027650

(methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT 725915-01-5

(unclaimed nucleotide sequence; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT 725915-02-6 725915-08-2

(unclaimed protein sequence; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

IT 725915-07-1

(unclaimed sequence; methods of screening test compds. using GADD34L, an eIF2 α -specific phosphatase subunit)

=> b home

FILE 'HOME' ENTERED AT 08:02:41 ON 14 SEP 2005

=>